7 Growth Hormone Secretagogues Ranked by Research Interest
Not all GH secretagogues are created equal. We ranked the top 7 by current research activity, mechanistic interest, and practical availability for laboratory investigation. For research purposes only.
1. CJC-1295 (with DAC) — The Long-Acting GHRH Analog
CJC-1295 with Drug Affinity Complex (DAC) sits at the top of our ranking because it represents the most pharmacologically sophisticated approach to sustained growth hormone releasing hormone (GHRH) receptor activation available for research. The DAC modification — a maleimidopropionic acid linker that binds irreversibly to serum albumin after injection — extends the peptide's half-life from minutes (typical for GHRH analogs) to approximately 6-8 days in animal models. This sustained signaling through the GHRH receptor produces pulsatile GH release that more closely mimics physiological patterns than bolus-injection GHRH analogs. Research interest in CJC-1295 with DAC is driven by its unique pharmacokinetic profile, which enables experimental designs investigating chronic GHRH receptor activation without the confounding variable of peak-and-trough drug levels. The peptide is based on a modified fragment of human GHRH(1-29) with amino acid substitutions at positions 2, 8, 15, and 27 that enhance receptor binding affinity and resistance to enzymatic degradation, with the DAC technology providing the extended duration of action.
2. Ipamorelin — The Selective Ghrelin Receptor Agonist
Ipamorelin (Aib-His-D-2Nal-D-Phe-Lys-NH2) ranks second for research interest because of its selectivity profile, which is unique among growth hormone secretagogues. Unlike other ghrelin receptor (GHS-R1a) agonists, Ipamorelin stimulates GH release with minimal effects on cortisol, prolactin, and ACTH levels in research models. This selectivity makes Ipamorelin an invaluable research tool for studying GH-specific effects without the confounding influences of other pituitary hormones. The peptide was originally developed by Novo Nordisk and progressed through early clinical trials before the program was discontinued — but the published data from those trials provided the research community with well-characterized pharmacological data that supports current preclinical research applications. For researchers studying the GH/IGF-1 axis in isolation from other endocrine pathways, Ipamorelin offers a cleaner experimental tool than less selective alternatives like GHRP-6 or GHRP-2.
3. Tesamorelin — The FDA-Acknowledged GHRH Analog
Tesamorelin is unique on this list because it has progressed through full regulatory evaluation, providing a level of clinical pharmacological characterization that other research peptides lack. As a synthetic analog of human GHRH(1-44) with a trans-3-hexenoic acid modification at the N-terminus, Tesamorelin represents the most thoroughly studied GHRH analog available. The extensive published clinical data provides researchers with detailed pharmacokinetic, pharmacodynamic, and safety information that informs preclinical research design. Research interest in Tesamorelin extends beyond its GH-releasing properties to its effects on hepatic fat metabolism and visceral adiposity, which were the primary endpoints in its clinical evaluation. For aging research, Tesamorelin is studied as a tool for understanding how restoring GHRH signaling affects age-related changes in body composition, metabolic function, and the GH/IGF-1 axis.
4. GHRP-6 — The Classic Ghrelin Mimetic
GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is one of the earliest synthetic growth hormone releasing peptides, and it remains one of the most widely used in research despite the availability of newer, more selective alternatives. Its enduring popularity in research is partly due to the massive body of published literature characterizing its effects — hundreds of studies spanning three decades provide a rich reference framework for experimental design and data interpretation. GHRP-6 acts primarily through the ghrelin receptor (GHS-R1a) but also influences appetite, gastric motility, and cortisol release — effects that are considered 'off-target' for GH research but are themselves subjects of active investigation. The peptide's strong appetite-stimulating effect, mediated through hypothalamic NPY/AgRP neuron activation, makes it a valuable tool for appetite and feeding behavior research in addition to its use in GH secretion studies. GHRP-6 is the workhorse of GH secretagogue research — not the most refined tool, but the one with the deepest literature support.
5. GHRP-2 — The More Potent GHRP-6 Successor
GHRP-2 (D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH2) is essentially the optimized successor to GHRP-6, with modifications to the amino acid sequence that increase GH-releasing potency and slightly alter the selectivity profile. Research has consistently shown GHRP-2 to be a more potent GH secretagogue than GHRP-6 on a per-dose basis, making it the preferred choice when maximizing GH release is the experimental objective. Like GHRP-6, GHRP-2 stimulates both GH and cortisol release, though the cortisol response is somewhat attenuated compared to GHRP-6. GHRP-2 also stimulates appetite, though the effect is generally reported as less pronounced than with GHRP-6. For researchers comparing GH secretagogue potency or studying dose-response relationships in the GH axis, GHRP-2 provides a useful complement to GHRP-6 — similar mechanism, higher potency, slightly different secondary effect profile. The availability of extensive comparative data between GHRP-2 and GHRP-6 makes them a natural pair for secretagogue comparison studies.
6. Hexarelin — The Strongest GH Pulse Producer
Hexarelin (His-D-2MeTrp-Ala-Trp-D-Phe-Lys-NH2) is widely regarded as the most potent growth hormone releasing peptide available for research, producing the largest acute GH release among the GHRP family. However, research has also demonstrated that Hexarelin is associated with more rapid desensitization of the GH response compared to other secretagogues — a phenomenon that limits its utility for chronic administration studies but makes it interesting for research into GHS-R1a receptor desensitization mechanisms. Beyond GH release, Hexarelin has attracted research interest for its cardiovascular effects, which appear to be mediated through a mechanism independent of the ghrelin receptor. Studies have demonstrated cardioprotective properties in animal models of ischemia, suggesting an additional receptor or binding site for Hexarelin that is distinct from GHS-R1a. This dual pharmacology — potent GH release through GHS-R1a plus cardiovascular effects through an unidentified pathway — makes Hexarelin a uniquely interesting research tool.
7. MK-677 (Ibutamoren) — The Oral Non-Peptide Secretagogue
MK-677 (Ibutamoren) is technically not a peptide — it is a small molecule ghrelin receptor agonist with oral bioavailability. We include it here because it is frequently discussed alongside peptide GH secretagogues and is increasingly found in the catalogs of peptide research suppliers. MK-677's primary research advantage is its oral bioavailability, which enables experimental designs requiring chronic administration without the daily injection protocols that peptide GH secretagogues require. Published clinical research demonstrated that MK-677 increased GH and IGF-1 levels with sustained efficacy over 12 months without significant tachyphylaxis — a notable contrast to Hexarelin's rapid desensitization. For aging research, MK-677 is studied as a tool for sustained GH axis activation with the practical advantage of oral dosing in animal models. Its long half-life (approximately 5 hours) provides relatively stable plasma levels compared to the brief peaks produced by injectable peptide secretagogues. While its non-peptide nature means it acts through slightly different binding kinetics at the ghrelin receptor compared to peptide agonists, it remains an essential research tool in the GH secretagogue field.
Research Disclaimer: All information on this page is provided for educational and research purposes only. Products discussed are intended for laboratory research use exclusively. They are not intended for human consumption, therapeutic use, or as dietary supplements. Always follow institutional guidelines and consult published peer-reviewed literature for research protocol development. Not for human consumption.